SecBot SecBot
8-K ·Filed Jun 17, 2026

RIGL

RIGEL PHARMACEUTICALS INC
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001034842-26-000043
8-K material event: Items 2.01
Actionable Insight • Neutral

The deal closure removes execution risk but the $70M cash outlay pressures near-term liquidity. Monitor Rigel's upcoming 10-Q for cash runway and initial VEPPANU revenue ramp. Milestone triggers and royalty start dates will be key catalysts.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$32.91
T+0 close · Jun 17, 2026 · via day close
Latest settled
+37.80%
T+60 · $45.35
Vs SPY
+35.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $32.91entry
  2. T+1 · 5mo ago +8.57%α +8.88% · $35.73
  3. T+5 · 5mo ago +12.40%α +14.06% · $36.99
  4. T+20 · 4mo ago +26.62%α +26.09% · $41.67
  5. T+60 · 2mo ago +37.80%α +35.91% · $45.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. The deal closed following HSR clearance, with Rigel paying the $70 million upfront cash consideration. This milestone de-risks the transaction but provides no new financial terms beyond the original announcement.

Key Facts

  • License agreement with Arvinas/Pfizer for VEPPANU (vepdegestrant) became effective on June 11, 2026.
  • Company paid a one-time upfront payment of $70.0 million to the licensors upon closing.
  • HSR waiting period terminated early and all other closing conditions satisfied.
  • Rigel granted exclusive global rights to develop, manufacture and commercialize VEPPANU.

Financial Impact

$70.0 million upfront cash payment (approximately 11.6% of $601M market cap); additional contingent milestones up to $320M plus royalties and up to $40M development cost reimbursement per prior disclosure.

cashdebtrevenuedilution

Risk Factors

  • Significant upfront cash payment may strain balance sheet if VEPPANU revenue ramp is slow.
  • Milestone payments and development cost reimbursements create future cash obligations beyond the upfront.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000043
Document: 0001034842-26-000043-index.html0001034842-26-000043
Document: 0001034842-26-000043.txt0001034842-26-000043

Track record

12 reports on RIGL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
  4. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
  5. Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
  6. Jun 17, 202621w ago 8-K Neutral 4/10 Viewing Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
  8. May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
  9. May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
  10. May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026